Premium
Botulinum toxin type A for drooling in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study
Author(s) -
Lagalla Giovanni,
Millevolte Marzia,
Capecci Marianna,
Provinciali Leandro,
Ceravolo Maria Gabriella
Publication year - 2006
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.20793
Subject(s) - drooling , sialorrhea , placebo , medicine , botulinum toxin , parkinson's disease , adverse effect , anesthesia , randomized controlled trial , surgery , disease , pathology , alternative medicine
To investigate the safety and efficacy of botulinum toxin type A (BoNTX) treatment to reduce sialorrhea in Parkinson's disease (PD), a double‐blind, randomized, placebo‐controlled study enrolled 32 PD patients complaining of excessive drooling. Patients received either 50 U Botox in each parotid gland or placebo without using ultrasound guidance. Subjects treated with BoNTX experienced a reduction in both drooling frequency and familial and social disability (Time × Group effect: P < 0.01), as well as in saliva production (Time × Group effect: P < 0.0001). No adverse events were recorded. BoNTX injections are safe and effective treatment for the management of PD‐related drooling. © 2006 Movement Disorder Society